| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0001 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.16 | 0.0001 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | -0.14 | 0.0001 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.17 | 0.0001 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | -0.14 | 0.0001 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | -0.22 | 0.0002 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.14 | 0.0002 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.22 | 0.0002 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.18 | 0.0003 |